Mobile

Study to investigate safety, tolerability, pharmacodynamics and pharmacokinetic properties of BAY 63-2521 after dosing of a 2 mg tablet in 20 patients with Raynaud’s phenomenon (RP)

Update Il y a 4 ans
Reference: EUCTR2013-001899-38

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of the study is to investigate the safety, tolerability and pharmacodynamics of a single oral dose of BAY 63-2521 administered in patients suffering from Raynaud’s phenomenon

Inclusion criteria

  • Patients with 1° and 2° Raynaud’s phenomenon (RP)

Links